CoChat

Repurposing doxycycline for synucleinopathies: remodelling of α-synuclein oligomers towards non-toxic parallel beta-sheet structured species

Open access
González-Lizárraga, Florencia, Socías, Sergio B., Ávila, César L., Torres-Bugeau, Clarisa M., Barbosa, Leandro R. S., Binolfi, Andres, Sepúlveda-Díaz, Julia E., Del-Bel, Elaine, Fernandez, Claudio O., Papy-Garcia, Dulce, Itri, Rosangela, Raisman-Vozari, Rita, Chehín, Rosana N. · 2017 · Scientific Reports

The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.

Abstract

Synucleinophaties are progressive neurodegenerative disorders with no cure to date. An attractive strategy to tackle this problem is repurposing already tested safe drugs against novel targets. In this way, doxycycline prevents neurodegeneration in Parkinson models by modulating neuroinflammation. However, anti-inflammatory therapy per se is insufficient to account for neuroprotection. Herein we characterise novel targets of doxycycline describing the structural background supporting its effectiveness as a neuroprotector at subantibiotic doses. Our results show that doxycycline reshapes α-synuclein oligomers into off-pathway, high-molecular-weight species that do not evolve into fibrils. Off-pathway species present less hydrophobic surface than on-pathway oligomers and display different β-sheet structural arrangement. These structural changes affect the α-synuclein ability to destabilize biological membranes, cell viability, and formation of additional toxic species. Altogether, these mechanisms could act synergically giving novel targets for repurposing this drug.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep41755

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of doxycycline on α-synuclein aggregation and seeding. (a) Fluorescence emission intensity of 25 μM thioflavin T in a solution containing 70 μM α-synuclein alone (empty circle), or with the addition of 100 μM doxycycline at 0 h (full circles), or after 16 h of incubation (inverted triangles) (doxycycline addition is indicated by an arrow). A solution containing 100 μM doxycycline alone (asterisk) is also shown as a control. (b) Transmission electron microscopy (TEM) of α-synuclein samples incubated at 37 °C under orbital agitation in the absence (top) or in the presence of doxycycline (bottom), and harvested after 16 h (left) or 96 h (right). The white bar corresponds to 200 nm at 220000X and 70000X magnification for observation of oligomers and fibrils respectively. (c) Fresh solutions of monomeric α-synuclein were seeded with oligomers preincubated in the absence (empty square) or in the presence of doxycycline (full square). The resulting solutions were incubated at 37 °C under orbital agitation and aggregation was assayed by ThT fluorescence emission. Unseeded aggregation kinetics are shown in (empty circle).
Figure 1 Effects of doxycycline on α-synuclein aggregation and seeding. (a) Fluorescence emission intensity of 25 μM thioflavin T in a solution containing 70 μM α-synuclein alone (empty circle), or with the addition of 100 μM doxycycline at 0 h (full circles), or after 16 h of incubation (inverted triangles) (doxycycline addition is indicated by an arrow). A solution containing 100 μM doxycycline alone (asterisk) is also shown as a control. (b) Transmission electron microscopy (TEM) of α-synuclein samples incubated at 37 °C under orbital agitation in the absence (top) or in the presence of doxycycline (bottom), and harvested after 16 h (left) or 96 h (right). The white bar corresponds to 200 nm at 220000X and 70000X magnification for observation of oligomers and fibrils respectively. (c) Fresh solutions of monomeric α-synuclein were seeded with oligomers preincubated in the absence (empty square) or in the presence of doxycycline (full square). The resulting solutions were incubated at 37 °C under orbital agitation and aggregation was assayed by ThT fluorescence emission. Unseeded aggregation kinetics are shown in (empty circle).CC BY · PubMed Central
Figure 2 Analysis of doxycycline binding to α-synuclein by NMR. (a) Overlaid contour plots of 1H-15N SOFAST-HMQC spectra of 70 μM monomeric α-synuclein in the absence (black) or presence (red) of 350 μM doxycycline. (b) 1H NMR spectra of 200 μM doxycycline alone (black line) or upon the addition of 100 μM monomeric α-synuclein (red line). (c) 1H NMR spectra of 200 μM doxycycline in the absence (black line) or presence of 100 μM α-synuclein aged for 8 h (red line), 24 h (blue line) or 48 h (green line). In panels (b) and (c), the asterisk denotes isolated doxycycline 1H signals that broaden upon binding to higher order amyloidogenic structures of α-synuclein. In panel (c), the symbol # denotes isolated monomeric α-synuclein signals vanishing as a consequence of the progression of the aggregation process. NMR spectra were acquired at 15 °C (a) and 25 °C (b) and (c). Samples were dissolved in 20 mM HEPES supplemented with 150 mM NaCl and 10% D2O.
Figure 2 Analysis of doxycycline binding to α-synuclein by NMR. (a) Overlaid contour plots of 1H-15N SOFAST-HMQC spectra of 70 μM monomeric α-synuclein in the absence (black) or presence (red) of 350 μM doxycycline. (b) 1H NMR spectra of 200 μM doxycycline alone (black line) or upon the addition of 100 μM monomeric α-synuclein (red line). (c) 1H NMR spectra of 200 μM doxycycline in the absence (black line) or presence of 100 μM α-synuclein aged for 8 h (red line), 24 h (blue line) or 48 h (green line). In panels (b) and (c), the asterisk denotes isolated doxycycline 1H signals that broaden upon binding to higher order amyloidogenic structures of α-synuclein. In panel (c), the symbol # denotes isolated monomeric α-synuclein signals vanishing as a consequence of the progression of the aggregation process. NMR spectra were acquired at 15 °C (a) and 25 °C (b) and (c). Samples were dissolved in 20 mM HEPES supplemented with 150 mM NaCl and 10% D2O.CC BY · PubMed Central
Figure 3 SAXS analysis of monomeric and oligomeric species of α-synuclein (a) SAXS curves from 175 μM α-synuclein incubated at 37 °C in the absence (red symbols) or presence (black symbols) of 250 μM doxycycline at 0 h (a), 2 h (b), 16 h (c) and 24 h (d). Corresponding distance distribution functions p(r) in the absence (e) or in the presence of doxycycline (f): 0 h (dark line); 2 h (red line), 16 h (blue line) and 24 h (magenta line).
Figure 3 SAXS analysis of monomeric and oligomeric species of α-synuclein (a) SAXS curves from 175 μM α-synuclein incubated at 37 °C in the absence (red symbols) or presence (black symbols) of 250 μM doxycycline at 0 h (a), 2 h (b), 16 h (c) and 24 h (d). Corresponding distance distribution functions p(r) in the absence (e) or in the presence of doxycycline (f): 0 h (dark line); 2 h (red line), 16 h (blue line) and 24 h (magenta line).CC BY · PubMed Central
Figure 4 FTIR spectra of the amide I region of 280 μM α-synuclein in deuterated buffer in the absence (blue line) or in the presence (red line) of 400 μM doxycycline after 0 h (a), 2 h (b) and 16 h (c) incubation at 37 °C, pD 7 under orbital agitation. Deconvolved spectra (top) was performed using a mixed Gaussian/ Lorentzian line shape of 18 cm−1 and a resolution enhancement factor of 2. Derivative spectra (bottom) were obtained with a power of three and a break-point of 0.3. Bis-ANS fluorescence signal of α-synuclein solution (70 μM) incubated at 37 °C under orbital agitation in the absence (d) or in the presence of 100 μM doxycycline (e). Aliquots of the samples were taken throughout time. All results shown are representative of at least four independent experiments.
Figure 4 FTIR spectra of the amide I region of 280 μM α-synuclein in deuterated buffer in the absence (blue line) or in the presence (red line) of 400 μM doxycycline after 0 h (a), 2 h (b) and 16 h (c) incubation at 37 °C, pD 7 under orbital agitation. Deconvolved spectra (top) was performed using a mixed Gaussian/ Lorentzian line shape of 18 cm−1 and a resolution enhancement factor of 2. Derivative spectra (bottom) were obtained with a power of three and a break-point of 0.3. Bis-ANS fluorescence signal of α-synuclein solution (70 μM) incubated at 37 °C under orbital agitation in the absence (d) or in the presence of 100 μM doxycycline (e). Aliquots of the samples were taken throughout time. All results shown are representative of at least four independent experiments.CC BY · PubMed Central
Figure 5 Modulation of α-synuclein oligomers cytotoxicity by doxycycline. (a) Cell viability, and (b) cell death of SH-SY5Y cells 24 h after the addition of 20 mM HEPES pH 7.4, 150 mM NaCl buffer (control), on-pathway α-synuclein oligomers, off-pathway α-synuclein oligomers, or on-pathway α-synuclein oligomers with doxycycline added to the culture medium. (c) Changes in liposomal membrane permeability upon the addition of the same species. The fluorescence signal was normalized by the signal observed after the addition of Triton X-100, which induced complete disruption of the vesicles. A monomeric solution of α-synuclein was also used as a negative control for cell viability, cytotoxicity and leakage assays. On-pathway, and off-pathway α-synuclein oligomers were prepared by incubating 140 μM α-synuclein in the absence, or in the presence of 200 μM doxycycline respectively for 16 h under orbital agitation at 37 °C.
Figure 5 Modulation of α-synuclein oligomers cytotoxicity by doxycycline. (a) Cell viability, and (b) cell death of SH-SY5Y cells 24 h after the addition of 20 mM HEPES pH 7.4, 150 mM NaCl buffer (control), on-pathway α-synuclein oligomers, off-pathway α-synuclein oligomers, or on-pathway α-synuclein oligomers with doxycycline added to the culture medium. (c) Changes in liposomal membrane permeability upon the addition of the same species. The fluorescence signal was normalized by the signal observed after the addition of Triton X-100, which induced complete disruption of the vesicles. A monomeric solution of α-synuclein was also used as a negative control for cell viability, cytotoxicity and leakage assays. On-pathway, and off-pathway α-synuclein oligomers were prepared by incubating 140 μM α-synuclein in the absence, or in the presence of 200 μM doxycycline respectively for 16 h under orbital agitation at 37 °C.CC BY · PubMed Central
Figure 6 Schematic diagram of the feedback relationship between α-synuclein, mitochondria and glial cells. The oligomeric species of α-synuclein provoke mitochondria fragmentation and ROS production is increased. ROS impacts on monomeric α-synuclein triggering its aggregation. The oligomeric α-synuclein released to the extracellular matrix inducing glia activation. Liberation of pro-inflammatory factors induces mitochondrial damage in an endless cycle. Doxycycline can interfere with this vicious circle blocking (i) α-synuclein oligomers nucleation and (ii) seeding, (iii) glia activation16, and (iv) ROS activity37.
Figure 6 Schematic diagram of the feedback relationship between α-synuclein, mitochondria and glial cells. The oligomeric species of α-synuclein provoke mitochondria fragmentation and ROS production is increased. ROS impacts on monomeric α-synuclein triggering its aggregation. The oligomeric α-synuclein released to the extracellular matrix inducing glia activation. Liberation of pro-inflammatory factors induces mitochondrial damage in an endless cycle. Doxycycline can interfere with this vicious circle blocking (i) α-synuclein oligomers nucleation and (ii) seeding, (iii) glia activation16, and (iv) ROS activity37.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 61 references

Cited by

Metadata

Authors
González-Lizárraga, F., Socías, S. B., Ávila, C. L., Torres-Bugeau, C. M., Barbosa, L. R. S., Binolfi, A., Sepúlveda-Díaz, J. E., Del-Bel, E., Fernandez, C. O., Papy-Garcia, D., Itri, R., Raisman-Vozari, R., & Chehín, R. N.
Affiliations
  • National University of Tucumán (AR)
  • Universidade de São Paulo (BR)
Corresponding author
Chehín, Rosana N.
Venue
Scientific Reports
Published
2017-02-03
Volume
7
Issue
1
Pages
41755-41755
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2584036292
Cited by
119
References
61
Citations by year
2026: 5 · 2025: 8 · 2024: 6 · 2023: 13 · 2022: 18 · 2021: 21 · 2020: 23 · 2019: 13 · 2018: 8 · 2017: 4
FWCI
9.15
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Americanae (AECID Library) (publishedVersion, other-oa)
  • HAL (submittedVersion, cc-by)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
  • Greater South Information System
Funders
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (2014/)
  • Consejo Nacional de Investigaciones Científicas y Técnicas (PIP-CONICET 0183)
  • Ministerio de Ciencia, Tecnología e Innovación Productiva
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Campus France
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
doxycycline, drug repurposing, synucleinopathies, alpha-synuclein oligomers, Parkinson's disease, neuroprotection, membrane perturbation, neuroinflammation, hydrophobic surfaces, neurodegeneration
MeSH terms
Protein Conformation, beta-Strand, Cell Survival, Doxycycline, Humans, Models, Molecular, Magnetic Resonance Spectroscopy, Protein Binding, Spectroscopy, Fourier Transform Infrared, Neurodegenerative Diseases, Cell Line, Tumor, alpha-Synuclein, Protein Multimerization, Drug Repositioning, Protein Aggregation, Pathological, Protein Aggregates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.